Dynavax Technologies Corporation

NasdaqGS:DVAX Stock Report

Market Cap: US$1.4b

Dynavax Technologies Future Growth

Future criteria checks 4/6

Dynavax Technologies is forecast to grow earnings and revenue by 42.9% and 18.9% per annum respectively while EPS is expected to grow by 40.5% per annum.

Key information

42.9%

Earnings growth rate

40.5%

EPS growth rate

Biotechs earnings growth24.9%
Revenue growth rate18.9%
Future return on equityn/a
Analyst coverage

Low

Last updated17 Jul 2024

Recent future growth updates

Recent updates

Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Jul 12
Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

May 22
Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain

May 10

Dynavax: Holding Firm Despite Its Missing Cash Cow

Mar 23

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Mar 06
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

Jan 31
Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Aug 02
These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

Jun 02
Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

May 03
We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Jan 16
Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Clover, Dynavax COVID-19 vaccine gets EU GMP certificate

Sep 20

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Sep 12
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

The Alphavaxers: Dynavax And Novavax, 2 Quarters On

Aug 22

Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats

Aug 04

Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Jun 03
Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Dynavax: Evolving Endemic Situation Adds To Its Risk

May 23

Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

May 12
Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

May 10
Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

Dynavax Technologies: Full Speed Ahead

Mar 01

Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Jan 28
Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Dynavax: A Coronavirus Growth Story

Jan 17

Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 18
Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

The Momentum Investor: Spotlight On Dynavax Technologies

Oct 25

Dynavax And TLR Biology: Long-Delayed But Outstanding Success

Oct 16

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well

Oct 02
These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well

Upgrade: Analysts Just Made A Meaningful Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts

Aug 10
Upgrade: Analysts Just Made A Meaningful Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts

Earnings and Revenue Growth Forecasts

NasdaqGS:DVAX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264076890994
12/31/20253494755705
12/31/2024285192255
3/31/202423695356N/A
12/31/2023232-696101N/A
9/30/202336161118122N/A
6/30/2023459111147152N/A
3/31/2023656236134141N/A
12/31/20227232935663N/A
9/30/2022733320140148N/A
6/30/2022674228142153N/A
3/31/2022470104238247N/A
12/31/202143972326336N/A
9/30/2021258-39192199N/A
6/30/2021163-6101105N/A
3/31/2021113-62-31-27N/A
12/31/202040-75-103-92N/A
9/30/202038-97-112-100N/A
6/30/202035-138-115-94N/A
3/31/202040-129-136-108N/A
12/31/201935-156-151-121N/A
9/30/201930-159-161-132N/A
6/30/201921-163-166-144N/A
3/31/201914-160-157-141N/A
12/31/20188-159-146-131N/A
9/30/20183-146-130-115N/A
6/30/20181-128-110-99N/A
3/31/20180-109-93-82N/A
12/31/20170-95N/A-78N/A
9/30/20178-89N/A-86N/A
6/30/20178-102N/A-97N/A
3/31/201710-111N/A-105N/A
12/31/201611-112N/A-107N/A
9/30/20164-118N/A-103N/A
6/30/20165-113N/A-97N/A
3/31/20164-108N/A-96N/A
12/31/20154-107N/A-93N/A
9/30/20156-102N/A-88N/A
6/30/20157-102N/A-88N/A
3/31/20158-103N/A-87N/A
12/31/201411-91N/A-74N/A
9/30/201412-90N/A-69N/A
6/30/201412-76N/A-58N/A
3/31/201413-68N/A-51N/A
12/31/201311-75N/A-59N/A
9/30/201310-74N/A-54N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DVAX's forecast earnings growth (42.9% per year) is above the savings rate (2.4%).

Earnings vs Market: DVAX's earnings (42.9% per year) are forecast to grow faster than the US market (14.8% per year).

High Growth Earnings: DVAX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: DVAX's revenue (18.9% per year) is forecast to grow faster than the US market (8.6% per year).

High Growth Revenue: DVAX's revenue (18.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DVAX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.